
Karen L. Reckamp, MD, MS, discusses targeted therapy options for rare mutations in non–small cell lung cancer.
Karen L. Reckamp, MD, MS, discusses targeted therapy options for rare mutations in non–small cell lung cancer.
This review will focus on current therapies used in the first-line setting for advanced EGFR mutation positive non–small cell lung cancer (NSCLC) followed by emerging data that may lead to a transition in the choice for initial therapy in these patients.
Published: August 16th 2024 | Updated: August 19th 2024
Published: March 18th 2024 | Updated: June 3rd 2024
Published: December 7th 2024 | Updated:
Published: December 12th 2022 | Updated:
Published: July 14th 2024 | Updated:
Published: May 18th 2023 | Updated: